AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 111 min read$AHCO

WOLF DALE B purchased $117K of AHCO (indirect holdings)

WOLF DALE B purchased 20,000 indirectly-held shares of AdaptHealth Corp. (AHCO) at $5.86 ($0.12M total) on 2026-08-07.

Original reporting
SEC EDGAR · WOLF DALE B
Published Aug 11, 2026, 12:02 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$AHCO
Bullish
medium confidence
Mentioned
$AHCO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AHCOBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (20,000 shares at $5.86, total $117,200) and the post-transaction share count (34,000).

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no accompanying fundamental update.

03

What to watch

The transaction is indirect and the article does not clarify the economic exposure or whether other holdings changed around the same time.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-10 for a 2026-08-07 purchase

Background

The article is a SEC Form 4 insider transaction disclosure for AdaptHealth Corp. (AHCO).

Company-level read

Ticker impact

$AHCOBullishMedium confidence
Context

AdaptHealth Corp. (AHCO) disclosed an insider Form 4 showing director Wolf Dale B bought 20,000 shares at $5.86 on 2026-08-07 via indirect holdings.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new operational or financial information beyond the trade details and there is no 10b5-1 plan.

Market effects

Sector

No sector read-through; this is a single-company insider transaction with no stated business development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buying can be routine or driven by personal liquidity needs, and the lack of a 10b5-1 plan does not guarantee a directional view on fundamentals.

Key entities

  • issuer
    AdaptHealth Corp.

    Subject of the Form 4 insider transaction disclosure (AHCO).

  • insider
    WOLF DALE B

    Director who reported an indirect open-market purchase of 20,000 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AHCO insider trading history →

Related articles

AUG 15
$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

mychesco.com6 min
AUG 11
$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

fool.com7 min
AUG 11
$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

yahoo.com6 min
AUG 9
$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

yahoo.com2 min
AUG 6
$AHCOHighAI 9/10

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.

yahoo.com4 min